Log in to save to my catalogue

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcin...

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcin...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_657146515d294ae39d54d915d166a66e

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

About this item

Full title

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Publisher

London: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A260-A261

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

BackgroundHHIs, vismodegib and sonidegib, are approved for treatment of patients with mBCC or locally advanced BCC who are not candidates for surgery or radiation. There is no approved option for patients who progress on or are intolerant to HHIs. Cemiplimab is an anti-programmed cell death-1 monoclonal antibody approved for treatment of patients w...

Alternative Titles

Full title

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_657146515d294ae39d54d915d166a66e

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_657146515d294ae39d54d915d166a66e

Other Identifiers

E-ISSN

2051-1426

DOI

10.1136/jitc-2020-SITC2020.0428

How to access this item